Cefiderocol/xeruborbactam (S-649228)
At this time, we are not offering Early Access for our investigational beta-lactam antibiotic/beta-lactamase inhibitor combination (S-649228) being studied for treatment of serious gram-negative infections. This is an investigational drug combination in an early stage of development and is currently available only through clinical trials. As additional studies are completed for this investigational drug combination, we may revisit this issue. โฏ
Ceftibuten/xeruborbactam (S-743229)
At this time, we are not offering Early Access for our investigational beta-lactam antibiotic/beta-lactamase inhibitor combination (S-743229) being studied for treatment of complicated urinary tract infections, including pyelonephritis. This is an investigational drug combination in an early stage of development and is currently available only through clinical trials. As additional studies are completed for this investigational drug combination, we may revisit this issue. โฏ